DAEWOONG CO.,LTD
003090 | KO
Overview
Corporate Details
- ISIN(s):
- KR7003090008
- LEI:
- Country:
- South Korea
- Address:
- 경기 성남시 중원구 상대원동 223-23, 성남시
- Website:
- https://www.daewoong.co.kr
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-15 00:00 |
Regulatory Filings
투자판단관련주요경영사항(자회사의 주요경영사항)
|
Korean | 14.9 KB | ||
| 2025-09-05 00:00 |
Regulatory Filings
투자판단관련주요경영사항(자회사의 주요경영사항)
|
Korean | 9.0 KB | ||
| 2025-08-14 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 3.7 MB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 4.0 MB | ||
| 2025-07-30 00:00 |
Regulatory Filings
투자판단관련주요경영사항(자회사의 주요경영사항)
|
Korean | 9.5 KB | ||
| 2025-06-02 00:00 |
Governance Information
기업지배구조보고서공시
|
Korean | 708.5 KB | ||
| 2025-05-16 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.7 KB | ||
| 2025-05-16 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 162.0 KB | ||
| 2025-05-16 00:00 |
Major Shareholding Notification
최대주주등소유주식변동신고서
|
Korean | 58.0 KB | ||
| 2025-05-15 00:00 |
Major Shareholding Notification
[기재정정]최대주주등소유주식변동신고서
|
Korean | 54.8 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 2.1 MB | ||
| 2025-05-14 00:00 |
Major Shareholding Notification
[기재정정]최대주주등소유주식변동신고서
|
Korean | 60.7 KB | ||
| 2025-04-16 00:00 |
Capital/Financing Update
단기차입금증가결정(자회사의 주요경영사항)
|
Korean | 11.5 KB | ||
| 2025-04-02 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.0 KB | ||
| 2025-04-01 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 62.4 KB |
Automate Your Workflow. Get a real-time feed of all DAEWOONG CO.,LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for DAEWOONG CO.,LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DAEWOONG CO.,LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops and manufactures prescription drugs like antibiotics and analgesics for global markets.
South Korea
080720
South Korea
080720
Developing AAV-based gene therapies for rare liver and central nervous system disorders.
United States of America
QURE
United States of America
QURE
Develops therapies for chronic diseases and manufactures organs for transplantation.
United States of America
UTHR
United States of America
UTHR
Manufactures, markets, and distributes TCM derivative products and biomedical drugs.
United States of America
UPC
United States of America
UPC
Vertically integrated biopharma firm developing medical cannabis treatments with a focus on CNS.
Israel
UNVO-M
Israel
UNVO-M
Developing a monoclonal antibody for severe inflammatory and respiratory diseases.
United States of America
UPB
United States of America
UPB
Develops non-surgical therapies for urological cancers using proprietary hydrogel technology.
United States of America
URGN
United States of America
URGN
Develops and commercializes vaccines for infectious diseases like chikungunya, Lyme, and Zika.
France
VLA
France
VLA
Develops and commercializes innovative therapies for central nervous system disorders.
United States of America
VNDA
United States of America
VNDA
Develops CAR-T and CAR-NK immunotherapies for solid tumors and canine lymphoma.
South Korea
323990
South Korea
323990